{"doc_id": "si-2021-0692-reg-1", "parent_doc_id": "si-2021-0692", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 692 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 14) Regulations 2021. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2021” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 14) regulation 2021 (2) collective citation medicinal product (prescription control supply) regulation 2003 2021 includes regulation", "start_char": 620, "end_char": 910, "source_path": "downloads\\2021\\2021_0692.pdf", "extraction_method": "pdfminer", "checksum": "sha256:13984c84fecf2e049afb36f6d937dfc95991b60c8dbec36dcfcdaa9817aab7e6", "cross_refs": []}
{"doc_id": "si-2021-0692-reg-2", "parent_doc_id": "si-2021-0692", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 692 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2021” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 13) Regulations 2021 (S.I. No. 605 of 2021).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2021 mean medicinal product (prescription control supply) (amendment) (no 13) regulation 2021 (s.i no 605 2021)", "start_char": 910, "end_char": 1226, "source_path": "downloads\\2021\\2021_0692.pdf", "extraction_method": "pdfminer", "checksum": "sha256:13984c84fecf2e049afb36f6d937dfc95991b60c8dbec36dcfcdaa9817aab7e6", "cross_refs": []}
{"doc_id": "si-2021-0692-reg-3", "parent_doc_id": "si-2021-0692", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 692 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of \n\n2021) to the Principal Regulations is amended— \n\n(a) by substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty concentrate for dispersion for \ninjection COVID-19 mRNA Vaccine (nucleoside modified)” the \nfollowing: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics, an additional or booster dose may be \nadministered to— \n\n(a) persons who are 16 years of age or older, and \n\n(b) \n\nimmunocompromised persons who are 12 years of \nage or older, \n\nwho have already received a primary vaccine course against \nCovid-19, at such volumes and intervals, and in such manner and \norder of prioritisation (whether by reference to age, employment \nsector, pregnancy or otherwise), as may be specified in such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”, and \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 17th December, 2021. \n\n \n \n \n \n \n \n \n\f[692] 3 \n\n(b) by substituting for the text in column 5 of the entry for the \nmedicinal product “Spikevax (previously Covid-19 Vaccine \nModerna) dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics, an additional or booster dose may be \nadministered to persons who are 30 years of age or older, who \nhave already received a primary vaccine course against Covid-19, \nat such volumes and intervals, and in such manner and order of \nprioritisation (whether by reference to age, employment sector, \npregnancy or otherwise), as may be specified \nin such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2021) principal regulation amended-- (a) substituting text column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristic additional booster dose may administered to-- (a) person 16 year age older (b) immunocompromised person 12 year age older already received primary vaccine course covid-19 volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained notice making statutory instrument published iris oifigiuil 17th december 2021 692 3 (b) substituting text column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristic additional booster dose may administered person 30 year age older already received primary vaccine course covid-19 volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained", "start_char": 1226, "end_char": 3363, "source_path": "downloads\\2021\\2021_0692.pdf", "extraction_method": "pdfminer", "checksum": "sha256:13984c84fecf2e049afb36f6d937dfc95991b60c8dbec36dcfcdaa9817aab7e6", "cross_refs": []}
{"doc_id": "si-2021-0692-reg-4", "parent_doc_id": "si-2021-0692", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 692 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\n2021) to the Principal Regulations is amended— \n\n(a) by substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty concentrate for dispersion for \ninjection COVID-19 mRNA Vaccine (nucleoside modified)” the \nfollowing: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics, an additional or booster dose may be \nadministered to— \n\n(a) persons who are 16 years of age or older, and \n\n(b) \n\nimmunocompromised persons who are 12 years of \nage or older, \n\nwho have already received a primary vaccine course against \nCovid-19, at such volumes and intervals, and in such manner and \norder of prioritisation (whether by reference to age, employment \nsector, pregnancy or otherwise), as may be specified in such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”, and \n\n(b) by substituting for the text in column 5 of the entry for the \nmedicinal product “Spikevax (previously Covid-19 Vaccine \nModerna) dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\n \n \n\f4 [692] \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics, an additional or booster dose may be \nadministered to persons who are 30 years of age or older, who \nhave already received a primary vaccine course against Covid-19, \nat such volumes and intervals, and in such manner and order of \nprioritisation (whether by reference to age, employment sector, \npregnancy or otherwise), as may be specified \nin such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”. \n\nGIVEN under my Official Seal, \n\n9 December, 2021. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f[692] 5", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2021) principal regulation amended-- (a) substituting text column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristic additional booster dose may administered to-- (a) person 16 year age older (b) immunocompromised person 12 year age older already received primary vaccine course covid-19 volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained (b) substituting text column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health 4 692 notwithstanding direction contrary summary product characteristic additional booster dose may administered person 30 year age older already received primary vaccine course covid-19 volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained  given official seal 9 december 2021 stephen donnelly minister health 692 5", "start_char": 3363, "end_char": 5500, "source_path": "downloads\\2021\\2021_0692.pdf", "extraction_method": "pdfminer", "checksum": "sha256:13984c84fecf2e049afb36f6d937dfc95991b60c8dbec36dcfcdaa9817aab7e6", "cross_refs": []}
{"doc_id": "si-2021-0692-explanatory-note", "parent_doc_id": "si-2021-0692", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 692 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to amend the relevant schedules in relation \nto the Comirnaty and Spikevax COVID-19 vaccines to take account of updated \nadvice in relation to booster and additional doses. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 14) Regulations 2021. \n\n \n \n \n \n \n \n \n \n\f6 [692] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.00 \n\n(DH-351) 75. 12/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation amend relevant schedule relation comirnaty spikevax covid-19 vaccine take account updated advice relation booster additional dos regulation may cited medicinal product (prescription control supply) (amendment) (no 14) regulation 2021 6 692 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.00 (dh-351) 75 12 21 propylon", "start_char": 5500, "end_char": 6577, "source_path": "downloads\\2021\\2021_0692.pdf", "extraction_method": "pdfminer", "checksum": "sha256:13984c84fecf2e049afb36f6d937dfc95991b60c8dbec36dcfcdaa9817aab7e6", "cross_refs": []}
